Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Ergosterol biosynthetic protein 28 homolog (ERG28) is a highly conserved, non-catalytic transmembrane protein involved in sterol biosynthesis pathways across eukaryotes. In yeast, ERG28 serves as a scaffold anchoring the C-4 demethylation enzyme complex (Erg25–Erg26–Erg27) to the endoplasmic reticulum, facilitating efficient ergosterol synthesis[1]. In mammals, ERG28 is homologous to yeast Erg28p and plays an ancillary role in cholesterol biosynthesis; it is co-regulated with core cholesterol enzymes by SREBP-2 and is expressed in most tissues[2]. Knockout studies in human cell lines show that loss of ERG28 significantly decreases cholesterol synthetic flux and cellular cholesterol levels. ERG28 interacts with itself and with key proteins of the demethylation complex (NSDHL, SC4MOL), indicating a structural, platform-like function[2]. Though not a direct enzymatic target, it is implicated in cancer cell proliferation and sterol homeostasis but is not currently a therapeutic target or direct drug interaction point[2].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ergosterol biosynthetic protein 28 homolog (ERG28).